Ofatumumab


What Is Ofatumumab? Leukemia
Research About This Site

Ofatumumab

Developed by a company called Genmad and marketed by Genmad and GlaxoSmithKline under the name Arzerra, ofatumumab is a monoclonal antibody and a cancer treatment. "Monoclonal antibody" refers to the method by which the drug is made. It also indicated to chemists and doctors that it is a very large and complex molecule. Antibodies are produced in the body in response to disease, and giving a patient an injection of a monoclonal antibody drug essentially amounts to supplementing the natural immune system - or immunotherapy.

Ofatumumab is approved by the Food and Drug Administration for the treatment of leukemia. It is specifically labeled for chronic lymphocytic leukemia. Oncologists can use the drug for other types of cancer if they feel it is the best course of action. This is called off-label use. The drug is under investigation for use in other cancers and it is possible that in the future the labelling could be expanded to include other indications.

This drugs has to be given by injection. If they were swallowed, the digestive system would denature and break it down before it could be absorbed into the bloodstream. Ofatumumab is mixed into a solvent for delivery through an intravenous system. A typical regimen is once-per-week administration for eight weeks, followed by less frequent administrations.

The most basic definition of cancer is abnormal cell growth. A mutation occurs in the cell's DNA and the normal cycle of cell growth and death becomes distorted. Cancer cells begin to grow out of control and unless stopped continue to replicate themselves until they form tumors. There are more that 200 different types of cancer; virtually any cell in the body has the potential to become cancerous. One of the more common types of cancer affects the lymphocytes and immune system. Two very closely related cancers of this type are chronic lymphocytic leukemia and follicular non-Hodgkin's lymphoma. Chronic lymphocytic leukemia affects the lymphocytes in the blood and the bone marrow while follicular non-Hodgkin's lymphoma affects the body's lymphocytes, lymph nodes, and bone marrow.

Rituximab is another monoclonal antibody that is used for CLL, but ofatumumab may turn out to be more effective.

There is also investigation into the use of ofatumumab for treatment of arthritis.

 

What Is Ofatumumab? Leukemia
Research About This Site